Advances in systemic therapy for malignant mesothelioma: future perspectives. (October 2017)

• Record Type: Journal Article
• Authors: Sobhani, Navid; Corona, Silvia Paola; Bonazza, Deborah; Ianza, Anna; Pivetta, Tania; Roviello, Giandomenico; Cortale, Maurizio; Guglielmi, Alessandra; Zanconati, Fabrizio; Generali, Daniele
• Is Part Of: Future oncology. Volume 13:Number 23(2017)
• Page Start: 2083
• Page End: 2101
• Publication Date: 2017-10
• Subjects: asbestos -- combinatorial chemotherapy -- epithelioid mesothelioma -- immunotherapy -- malignant mesothelioma -- targeted therapy; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2017-0224
• Languages: English
• ISSNs: 1479-6694

Abstract

Malignant mesothelioma is a rare and aggressive form of cancer affecting the mesothelium. This mainly occupational disease is becoming more common in those countries where asbestos has been used for industrial applications. Notwithstanding the progress made in the field, patients do not survive more than 12 months on average with standard treatment. With the advent of next generation sequencing, it is now possible to study the mutational landscape of each tumor with the aim of identifying the genetic aberrations driving tumorigenesis. This review encompasses the latest research in the field, with particular attention to new chemotherapy combinatorial regimens, molecular targets and immunotherapies, providing a comprehensive picture of the current and future treatment options for malignant mesothelioma patients.